Extended-release niacin decreases serum fetuin-A concentrations in individuals with metabolic syndrome

被引:42
|
作者
Kaushik, Shalini V. [1 ,2 ]
Plaisance, Eric P. [2 ,3 ]
Kim, Teayoun [1 ,2 ]
Huang, Edmond Y. [1 ,2 ]
Mahurin, A. Jack [5 ]
Grandjean, Peter W. [2 ,4 ]
Mathews, Suresh T. [1 ,2 ]
机构
[1] Auburn Univ, Dept Nutr & Food Sci, Auburn, AL 36849 USA
[2] Auburn Univ, Boshell Diabet & Metab Dis Res Program, Auburn, AL 36849 USA
[3] Auburn Univ, Dept Anat Physiol & Pharmacol, Auburn, AL 36849 USA
[4] Auburn Univ, Dept Kinesiol, Auburn, AL 36849 USA
[5] Baptist Family Med Residency Program, Montgomery, AL 36116 USA
关键词
fetuin-A; niacin; Niaspan; alpha 2-HS glycoprotein; metabolic syndrome; triglycerides; MOLECULAR-WEIGHT ADIPONECTIN; RECEPTOR TYROSINE KINASE; INSULIN-RESISTANCE; NICOTINIC-ACID; INFLAMMATORY MARKERS; MEDIA THICKNESS; PLASMA; ASSOCIATION; INHIBITOR; GENE;
D O I
10.1002/dmrr.967
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Fetuin-A, a liver-secreted phosphoprotein and physiological inhibitor of insulin receptor tyrosine kinase, is associated with insulin resistance, metabolic syndrome (MetS), and an increased risk for type 2 diabetes. However, studies on the modulation of circulating levels of fetuin-A are limited. The goal of this study was to determine the effect of niacin administration on serum total- and phosphorylated fetuin-A (phosphofetuin-A) concentrations in individuals with MetS and correlate with changes in serum lipids, insulin sensitivity, and markers of inflammation. Methods Fifteen sedentary, obese, male participants, who met the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria for MetS, were treated with extended-release niacin (Niaspan) for 6 weeks. Blood samples were obtained before and after treatment with niacin. Results Serum fetuin-A and phosphofetuin-A concentrations were decreased following niacin administration (p < 0.005). Changes in fetuin-A concentrations were correlated with changes in triglyceride (r = 0.62, p = 0.01) and C-reactive protein (CRP) concentrations (r = 0.58, p, < 0.05) after nacin treatment. Changes in high-density lipoproteins (HDL)-cholesterol following niacin intervention were negatively correlated with changes in serum fetuin-A (p < 0.05) and phosphofetuin-A concentrations (p < 0.05). Serum cortisol levels were significantly elevated after niacin administration. Conclusions Niacin treatment lowers serum total- and phosphofetuin-A concentrations in individuals with MetS, and these changes correlate with the beneficial changes in serum lipids. Because niacin is known to induce insulin resistance, these findings suggest that fetuin-A may not be a mediator of niacin-induced insulin resistance but it may blunt the insulin resistance induced by niacin by decreasing its circulating concentrations. Copyright (c) 2009 John Wiley & Sons, Ltd.
引用
收藏
页码:427 / 434
页数:8
相关论文
共 50 条
  • [1] Serum fetuin-A is correlated with metabolic syndrome in middle-aged and elderly Chinese
    Xu, Yu
    Xu, Min
    Bi, Yufang
    Song, Aiyun
    Huang, Yun
    Liu, Yu
    Wu, Yaohua
    Chen, Yuhong
    Wang, Weiqing
    Li, Xiaoying
    Ning, Guang
    ATHEROSCLEROSIS, 2011, 216 (01) : 180 - 186
  • [2] Extended-release niacin raises adiponectin and leptin
    Westphal, Sabine
    Borucki, Katrin
    Taneva, Elena
    Makarova, Ruma
    Luley, Claus
    ATHEROSCLEROSIS, 2007, 193 (02) : 361 - 365
  • [3] Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome
    Bays, Harold E.
    Shah, Arvind
    Lin, Jianxin
    Sisk, Christine McCrary
    Paolini, John F.
    Maccubbin, Darbie
    JOURNAL OF CLINICAL LIPIDOLOGY, 2010, 4 (06) : 515 - 521
  • [4] Fetuin-A serum concentrations in healthy children
    Wigger, Marianne
    Schaible, Jan
    Muscheites, Jutta
    Kundt, Guenther
    Haffner, Dieter
    Fischer, Dagmar-Christiane
    ANNALS OF CLINICAL BIOCHEMISTRY, 2009, 46 : 511 - 513
  • [5] The Relationship Between Serum Fetuin-A, Cystatin-C Levels, and Microalbuminuria in Patients With Metabolic Syndrome
    Huddam, Bulent
    Azak, Alper
    Kocak, Gulay
    Bayraktar, Nilufer
    Sezer, Siren
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2013, 27 (04) : 317 - 322
  • [6] Fenofibrate and extended-release niacin improve the endothelial protective effects of HDL in patients with metabolic syndrome
    Gomaraschi, Monica
    Ossoli, Alice
    Adorni, Maria Pia
    Damonte, Elisabetta
    Niesor, Eric
    Veglia, Fabrizio
    Franceschini, Guido
    Benghozi, Renee
    Calabresi, Laura
    VASCULAR PHARMACOLOGY, 2015, 74 : 80 - 86
  • [7] Fetuin-A levels in obesity: differences in relation to metabolic syndrome and correlation with clinical and laboratory variables
    Ismail, Nagwa Abdallah
    Ragab, Shadia
    Abd El Dayem, Soha M.
    Abd ElBaky, Abeer
    Salah, Nehal
    Hamed, Mona
    Assal, Heba
    Koura, Hala
    ARCHIVES OF MEDICAL SCIENCE, 2012, 8 (05) : 826 - 833
  • [8] Extended-release Niacin Acutely Suppresses Postprandial Triglyceridemia
    Usman, M. Haris U.
    Qamar, Arman
    Gadi, Ramprasad
    Lilly, Scott
    Goel, Harsh
    Hampson, Jaison
    Mucksavage, Megan L.
    Nathanson, Grace A.
    Rader, Daniel J.
    Dunbar, Richard L.
    AMERICAN JOURNAL OF MEDICINE, 2012, 125 (10) : 1026 - 1035
  • [9] Serum Fetuin-A levels in women with polycystic ovary syndrome
    Gulhan, Ibrahim
    Bozkaya, Giray
    Oztekin, Deniz
    Uyar, Ibrahim
    Kebapcilar, Ayse Gul
    Pamuk, Baris
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2012, 286 (06) : 1473 - 1476
  • [10] Niacin Extended-Release/Simvastatin
    Mark Sanford
    Monique P. Curran
    Drugs, 2008, 68 : 2373 - 2386